The following are key events that we have chosen to highlight in the report:

• Further Progress in the Clinical Development
• Strengthened Patent Portfolio
• New Experienced Board Members
• Increased Cost Base Compared to Previous Quarter
• Financial Position Bolstered by Convertible Loans and New Credit Facility Obtained in the Beginning of 2024

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of comments on Pharma Equity Group. Readers may assume that Analyst Group has received compensation for making the commentary. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.